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A B S T R A C T
Background: Dietary protein restriction is emerging as an alternative approach to treat obesity and glucose
intolerance because it markedly increases plasma fibroblast growth factor 21 (FGF21) concentrations. Similarly,
dietary restriction of methionine is known to mimic metabolic effects of energy and protein restriction with
FGF21 as a required mechanism. However, dietary protein has been shown to be required for normal bone
growth, though there is conflicting evidence as to the influence of dietary protein restriction on bone re-
modeling. The purpose of the current study was to evaluate the effect of dietary protein and methionine re-
striction on bone in lean and obese mice, and clarify whether FGF21 and general control nonderepressible 2
(GCN2) kinase, that are part of a novel endocrine pathway implicated in the detection of protein restriction,
influence the effect of dietary protein restriction on bone.
Methods: Adult wild-type (WT) or Fgf21 KO mice were fed a normal protein (18 kcal%; CON) or low protein
(4 kcal%; LP) diet for 2 or 27 weeks. In addition, adult WT or Gcn2 KO mice were fed a CON or LP diet for
27 weeks. Young New Zealand obese (NZO) mice were placed on high-fat diets that provided protein at control
(16 kcal%; CON), low levels (4 kcal%) in a high-carbohydrate (LP/HC) or high-fat (LP/HF) regimen, or on high-
fat diets (protein, 16 kcal%) that provided methionine at control (0.86%; CON-MR) or low levels (0.17%; MR)
for up to 9 weeks. Long bones from the hind limbs of these mice were collected and evaluated with micro-
computed tomography (μCT) for changes in trabecular and cortical architecture and mass.
Results: In WT mice the 27-week LP diet significantly reduced cortical bone, and this effect was enhanced by
deletion of Fgf21 but not Gcn2. This decrease in bone did not appear after 2 weeks on the LP diet. In addition,
Fgf21 KO mice had significantly less bone than their WT counterparts. In obese NZO mice dietary protein and
methionine restriction altered bone architecture. The changes were mediated by FGF21 due to methionine re-
striction in the presence of cystine, which did not increase plasma FGF21 levels and did not affect bone ar-
chitecture.
Conclusions: This study provides direct evidence of a reduction in bone following long-term dietary protein
restriction in a mouse model, effects that appear to be mediated by FGF21.
1. Introduction
Dietary restrictions of nutrients, including protein, have been
utilized to treat various disorders in humans, including chronic kidney
disease, for hundreds of years (Aparicio et al., 2012; Mandayam and
Mitch, 2006). Dietary restriction also extends life span in both humans
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and animals (Leto et al., 1976; Mair and Dillin, 2008); however, the
benefit of these diets with respect to one organ system is at times offset
by detrimental effects found in other organ systems. Protein provides
essential amino acids for the synthesis of bone collagen matrix, and
dietary protein restriction has been associated with a reduction in bone
density in humans (Ammann et al., 2000) and in animal models
(Bourrin et al., 2000; Huang et al., 2014; Mardon et al., 2008). In an
elderly population, protein malnutrition has been attributed to a re-
duction in bone mass and subsequent osteoporosis (Rizzoli and Bonjour,
2004; Rizzoli, 2008; Rizzoli et al., 2014). Similarly, a positive correla-
tion between bone mineral density (BMD) and both energy and protein
intake have been reported, especially in the aged population (Devine
et al., 2005; Hannan et al., 2000). Recently a gap has been identified in
the literature evaluating the involvement of dietary nutrient restric-
tions, including protein restriction, on bone quality, indicating that the
majority of studies focus on evaluating only BMD, which does not
provide a broad picture of bone health (Huang and Ables, 2016). While
BMD is still the “gold standard” diagnostic test for evaluating overall
bone health and fracture risk in humans (Fonseca et al., 2014; NIH
Consensus Development Panel on Osteoporosis Prevention, Diagnosis,
2001), in animal models there have been advances in the field of
imaging of bone and surrounding tissue which have significantly en-
hanced the evaluation of volumetric BMD as well as bone geometry in
both trabecular and cortical bone in numerous locations. Specifically,
micro-computed tomography (μCT) allows complete evaluation of these
parameters in rodents, providing an opportunity to fully evaluate the
potential impact of these dietary restrictions on bone health (Bouxsein
et al., 2010). In addition, a large portion of the literature reporting
impacts of insufficient protein on skeletal tissue has been conducted in
either animal models of bone growth, or in cohorts that represent the
impacts on aged bone remodeling (Ammann et al., 2000; Brennan-
Speranza et al., 2011; Rouy et al., 2014). There are very few studies that
evaluate these changes in animal models that do not have confounding
comorbidities associated with advanced age, or outside of young, ske-
letally immature animals that are potentially more sensitive to changes
in nutrient restriction.
Dietary restrictions, such as methionine restriction, have been
shown to regulate metabolism through inconsistent mechanisms
(Wanders et al., 2014). Fibroblast growth factor 21 (FGF21) is ex-
pressed in numerous tissues, especially the liver (So and Leung, 2016),
and an increase in circulating FGF21 has been associated with meta-
bolic responses to protein restrictions (Laeger et al., 2016; Laeger et al.,
2014a) and fasting (Inagaki et al., 2008; Guan et al., 2016). General
control nonderepressible 2 (GCN2) kinase has been reported as an up-
stream regulator of FGF21 during a short-term but not long-term
dietary protein restriction (Laeger et al., 2016; Laeger et al., 2014a).
GCN2 phosphorylates the eukaryotic initiation factor 2 alpha in re-
sponse to depletion of cellular amino acids (Wek et al., 1995), which
results in the activation of the activating transcription factor 4, which
binds to the FGF21 promoter that contains amino acid response ele-
ments (Laeger et al., 2016; De Sousa-Coelho et al., 2012). FGF21 has
also been implicated in the regulation of bone homeostasis following
nutrient restriction, including protein, in humans (Fazeli et al., 2015;
Lee et al., 2013). In patients afflicted with anorexia nervosa, a disorder
in which individuals experience self-induced starvation, a significant
inverse correlation has been found between circulating FGF21 levels
and bone mass (Fazeli et al., 2015). In mouse models evaluating FGF21
effects on bone, transgenic mice with FGF21 overexpression and mice
with high circulating levels of FGF21 secondary to methionine restric-
tion have been identified as having low bone density (Ables et al., 2012;
Wei et al., 2012). On the contrary, a study in humans has shown a
strong positive correlation between plasma FGF21 levels and BMD in
healthy women (Lee et al., 2013). Similarly, a recent report suggests
that increased circulating FGF21 does not regulate bone homeostasis in
either direction (Li et al., 2016a). Thus, there appears to be conflicting
evidence regarding the precise role of FGF21 in bone homeostasis, and
whether it plays a similar role in the presence of dietary protein re-
striction and/or comorbidities. In addition, the upstream regulator of
FGF21, GCN2, has not been explored as a possible mediator in this
process. Therefore, the purpose of the current study was to system-
atically evaluate the impact of dietary protein and methionine restric-
tion on bone quality in adult and young mice, and clarify whether there
is an involvement of FGF21 and GCN2 in this process. Lastly, obesity is
known to affect bone, particularly during development, however the
specific impacts and mechanisms are unclear (Farr and Dimitri, 2017;
Shapses et al., 2017). Therefore, we tested the effect of these diets in an
obese mouse model to identify whether obesity influenced the impact of
a protein restricted diet.
2. Methods
2.1. Animals & study design
All animal procedures with mice on C57BL/6 background and NZO/
HIBomDife mice were approved by the Pennington Biomedical
Research Center Institutional Animal Care and Use Committee and by
the animal welfare committees of DIfE and local authorities (Landesamt
für Umwelt, Gesundheit und Verbraucherschutz, Brandenburg,
Germany), respectively. Male C57BL/6 mice (Jackson Laboratory, Bar
Harbor, ME, USA) were used, and Fgf21-deficient mice on a C57BL/6
background were provided by Dr. Steven Kliewer (University of Texas
Southwestern) as previously described (Potthoff et al., 2009). Gcn2-
deficient mice on the C57BL/6 background were purchased from
Jackson Laboratory (Stock #008240). NZO/HIBomDife mice were bred
in house at the DIfE. All mice were single housed in a 12:12 h light:dark
cycle with ad libitum access to food or water unless otherwise noted.
To identify the long-term impact of dietary protein restriction, two
separate experiments were conducted with Fgf21-deficient (Fgf21-KO)
or Gcn2-deficient (Gcn2-KO) and a group of wild-type (WT) mice. Mice
were initially adapted to a control diet for five days, and at
14–15 weeks of age, mice of each genotype were divided into two
groups and were placed on either a normal protein (CON; outlined
below in Section 2.2) or low protein (LP; outlined below in Section 2.2)
diet. The Fgf21 long term study included n = 10/group, with a total of
40 animals; the Gcn2 long-term study included n = 8/group, with a
total of 32 animals. Animals were maintained on these diets for
27 weeks, at which point they were sacrificed, and tissues were col-
lected for analysis.
To evaluate whether there was a short-term effect of dietary protein
restriction on bone architecture, Fgf21-KO and WT mice were initially
adapted to a control diet for five days. At 10 weeks of age, mice of each
genotype were divided into two groups (n = 10/group, total of 40
animals) and placed on either a normal protein (CON) or low protein
(LP) diet. Animals were maintained on these diets for 14 days, at which
point they were sacrificed and bones were collected for analysis.
In addition, to evaluate the effect of dietary protein and methionine
restriction on bone under obese conditions, after weaning male New
Zealand obese (NZO) mice, a model for polygenic obesity and type 2
diabetes, were placed on high-fat diets (outlined below in Section 2.2)
that provided protein at control (CON) levels, low protein in the context
of either high-carbohydrate (LP/HC) or high-fat (LP/HF) regimen, or on
high-fat diets without lowering the protein content that provided me-
thionine at control (CON-MR) with cystine, or low levels (MR) with
cystine, and MR without cystine for up to 9 weeks. At the end of the
study mice were sacrificed and tissues were collected for analysis.
Intact hind limbs were collected at necropsy and fixed in 10%
neutral-buffered formalin. Femurs (FGF21 long-term study, GCN2 long-
term study) and tibiae (FGF21 short-term study) were disarticulated
and dissected free from soft tissue for subsequent micro-computed to-
mography (μCT) scanning and histology, as outlined below.
A detailed dietary composition and data related to changes in body
weight and composition, blood glucose, plasma insulin, plasma FGF21,
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energy expenditure, and food intake have been previously published for
all these mice (Laeger et al., 2016; Laeger et al., 2014a; Laeger et al.,
2018; Castaño-Martinez et al., 2019).
2.2. Dietary compositions
Control (normal protein, CON) and low protein (LP) diets were
formulated and produced by Research Diets (New Brunswick, NJ, USA),
and were designed to be isocaloric by equally varying protein and
carbohydrate content while keeping fat constant. The CON diet con-
tained 18% casein (by weight) as the protein source (18 kcal% protein,
60 kcal% carbohydrate, 22 kcal% fat), while the LP diet contained 5%
casein (4 kcal% protein, 74 kcal% carbohydrate, 22 kcal% fat). A de-
tailed dietary composition has been previously published (Laeger et al.,
2016).
High fat diets were formulated as outlined: control (CON; 16 kcal%
protein, 51 kcal% carbohydrate, 33 kcal% fat), low protein levels in a
high-carbohydrate (LP/HC; 4 kcal% protein, 63 kcal% carbohydrate,
33 kcal% fat) or low protein levels with high-fat (LP/HF; 4 kcal%
protein, 49 kcal% carbohydrate, 47 kcal% fat) regimen. High-fat diets
(16 kcal% protein, 52 kcal% carbohydrates, 32 kcal% fat) provided
methionine at control (CON-MR; 0.86%) or low levels (MR; 0.17%)
with cystine (0.3%) or without.
2.3. Micro-computed tomography (μCT)
For studies involving mice on the C57BL/6 background, samples
were placed in holders with appropriate fluid (70% ETOH) for scanning
by μCT (Scanco Model 40; Scanco Medical AG, Bassersdorf,
Switzerland). The samples were scanned in a coronal plane at 55 kV,
0.3-second integration time, with a 10 μm voxel size in plane and a
10 μm slice thickness. The lengths of the bones were determined from
the scans. The greater trochanter in the mouse extends further proxi-
mally than the femoral head, therefore to remain consistent in mea-
surements, the bones were measured using transverse μCT slices from
the proximal tip of the greater trochanter to the distal edge of the fe-
moral condyles. The regions of interests (ROIs) for tissue analysis in the
femur were determined to be the distal 30% of the femur to the distal
physis for trabecular bone, and midshaft (50% of the length of the
femur) for cortical bone. The ROIs for tissue analysis in the tibia were
determined to be the proximal 30% of the tibia to the proximal physis
for trabecular bone, and midshaft (50% of the length of the tibia) for
cortical bone. The proper thresholds for both trabecular and cortical
bone were tested and the same thresholds were used throughout the
study. For trabecular bone, total volume (TV, mm3), bone volume (BV,
mm3), BV/TV, bone surface (BS, mm2), BS/BV, tissue density, apparent
density, trabecular number (Tb.N, 1/mm), trabecular thickness (Tb.Th,
mm), trabecular spacing (Tb.Sp, mm), connectivity density (Conn.D, 1/
mm3), structural model index (SMI), and degree of anisotropy (DA)
were evaluated. For cortical bone, total cortical area (Tt.Ar, mm2),
cortical bone area (Ct.Ar, mm2), bone area/total area (BA/TA), thick-
ness (Ct.Th, mm), porosity (Ct.Po, %), marrow area (Ma.Ar, mm2),
polar moment of inertia (J, mm4), and bone mineral density (BMD, mg
HA/ccm) were evaluated. All variables use established published pro-
cedures and nomenclature (Bouxsein et al., 2010).
For studies involving NZO mice μ-CT analysis was conducted with
LaTheta LCT-200 (Hitachi-Aloka) using manufacturer's pre-defined
parameters for isolated bone measurements of bone slices with 24 μm
thickness. A region of interest was scanned 25 slices from the distal
growth plate extending 100 slices proximally towards the diaphysis. For
trabecular bone, trabecular area ratio (%), total bone mineral density
(mg/cm3), plane bone mineral density (g/cm2), and polar moment (mg
x cm) were evaluated. For cortical bone, thickness (mm) and cortical
area ratio (%) were evaluated.
2.4. Histopathology
Following μCT analysis, femurs from both studies (Fgf21-KO and
Gcn2-KO) that were fed the LP diet for 27 weeks were decalcified with
10% EDTA and prepared for routine histological processing. Two
midcoronal sections for each femur were prepared and stained with
hematoxylin & eosin (H&E). Care was taken to include the distal epi-
physis, physis, and metaphysis of each bone within the section for
evaluation by a board-certified veterinary pathologist. Sections were
evaluated to qualitatively confirm μCT findings and characterize any
potential changes identified within the distal physis for potential im-
pacts of dietary protein restriction and/or Fgf21 deficiency on growth.
In addition, any other abnormalities in surrounding tissue (marrow
contents, vasculature) were noted.
2.5. Statistics
Data were analyzed using software Prism 6 (GraphPad Software,
San Diego, CA, USA) applying two-way ANOVA (with Bonferroni post-
hoc analyses) or unpaired two-tailed t-test. All data are expressed as
means± SEM, with a probability value of 0.05 considered statistically
significant.
3. Results
3.1. FGF21 is required for long-term low-protein-induced changes in
femoral cortical morphology, but not trabecular morphology
At week 27 on a diet, compared to CON WT mice, plasma levels of
FGF21 were robustly increased in LP WT mice (Laeger et al., 2016).
Neither WT nor Fgf21 KO mice showed a diet effect in regard to the
femur length (Fig. 1A) upon 27-week dietary protein restriction. LP WT
mice showed a significantly lower femoral cortical thickness, cortical
total area (TA), cortical bone area/total area (BA/TA), cortical polar
moment of inertia (pMOI), and significantly increased cortical bone
porosity in comparison to CON WT mice (Fig. 1B–F). All these effects
were lost in the Fgf21 KO mice (Fig. 1). In regard to the femoral tra-
becular bone, LP WT mice showed significantly decreased bone vo-
lume/total volume (BV/TV), a lower trabecular number, and lower
trabecular connectivity density compared to CON WT mice, dietary
effects which could be observed in the Fgf21 KO mice on LP diet as well
(Fig. 1H, I, K), without a significant interaction found between strain
and diet. The trabecular thickness was only lower by number in WT
mice on a LP diet compared to CON WT mice (Fig. 1J). This change was
also evident in qualitative histopathological evaluation; the amount of
trabecular bone was markedly decreased in quantity in the Fgf21 KO on
LP diet compared to all other groups (data not shown). Due to varia-
bility in plane of section, more detailed histologic evaluation of the
trabecular bone could not be performed. The physes of all sections were
inactive and there were no discernable histologic abnormalities in any
section. Neither WT nor Fgf21 KO mice showed a dietary impact on
femoral trabecular total volume (Fig. 1G). In summary, a LP diet re-
sulted in both cortical and trabecular bone loss, with FGF21 being re-
quired for the effects of LP diet on cortical but not trabecular bone.
3.2. Short-term protein restriction does not induce changes in tibia
morphology
In contrast to the 27-week diet data outlined above, no diet effects
in the tibia could be observed in WT and Fgf21 KO mice after 2 weeks
on a LP diet in respect to cortical thickness, cortical TA, cortical BA/TA,
cortical pMOI, cortical bone porosity, and marrow area (Fig. 2A–F), or
tibial length, despite increased plasma FGF21 levels in WT LP mice
(Laeger et al., 2014b). However, there appeared to be a potential early,
though insignificant, effect of a reduced protein diet on trabecular bone
volume in WT mice, where the BV/TV was lower in LP vs. CON fed mice
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(Fig. 2H). Other trabecular parameters were not different between CON
and LP fed WT or Fgf21 KO mice (Fig. 2G, I, J, K).
3.3. GCN2 is not required for long-term low-protein-induced changes in
femoral morphology
A similar study to the chronic LP study using WT and Fgf21 KO mice
was conducted in Gcn2-deficient mice, and a summary of these data is
presented in Fig. 3. In contrast to Fgf21 KO mice, the Gcn2 KO mice
responded in the same way as the WT mice on a LP diet. Also, circu-
lating FGF21 levels were increased in Gcn2 KO mice on a low protein
diet (Laeger et al., 2016). In detail, femoral cortical thickness, cortical
TA, cortical BA/TA, and cortical pMOI were significantly lower in both
strains (WT and Gcn2 KO) as a response to a LP diet (Fig. 3B, C, D, F).
The cortical bone porosity was significantly increased in both WT and
Gcn2 KO mice on a LP diet (Fig. 3E). In respect to the trabecular bone,
the total volume, BV/TV, trabecular number, trabecular thickness, and
connectivity density were significantly lower in both WT and Gcn2 KO
mice on a LP diet compared to mice on a CON diet (Fig. 3G–K). Qua-
litative histopathologic evaluation of the trabecular bone was similar
for all WT mice regardless of diet, however the Gcn2 KO mice fed the
control (CON) diet had a noticeable decrease in trabecular bone as
compared to both of the WT groups, and the Gcn2 KO mice fed the low
protein (LP) diet had decreased trabecular bone as compared to both
the WT groups and the Gcn2 KO CON group (data not shown). Again,
due to variability in plane of section, more detailed histologic
Fig. 1. FGF21 is required for long-term low-protein-induced changes in femoral morphology. At 14–15 weeks of age, wild-type (WT) and FGF21-deficient (Fgf21 KO)
mice were placed on a control (CON) diet for 5 days, at which point a random subgroup of mice was transferred to the low-protein (LP) diet for 27 weeks. (A) Femur
length. Femoral cortical (B) thickness, (C) total area, (D) BA/TA, (E) bone porosity, and (F) pMOI. Femoral trabecular (G) total volume, (H) BV/TV, (I) number, (J)
thickness, and (K) connectivity density. Data are presented as means± SEM (n = 10/group). Differences were calculated by using two-way ANOVA. Mean values
with different lowercase letters differ with P ≤ 0.05.
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evaluation of trabecular bone could not be performed. The physes of all
sections were inactive and there were no discernable abnormalities in
any section. In summary, unlike in the chronic Fgf21 KO study, Gcn2
depletion did not blunt these changes, and a reduction in cortical in-
tegrity was still identified in the Gcn2 KO mice on LP diet compared to
CON diet.
3.4. Dietary protein restriction alters bone architecture in New Zealand
Obese mice
To evaluate the effect of dietary protein restriction on bone under
obese conditions, NZO mice, a model for polygenic obesity, were placed
on high-fat diets that provided protein at control (CON); low protein
levels with high levels of carbohydrates (LP/HC); or a low-protein,
high-fat (LP/HF) regimen for 8 weeks. Both dietary protein restrictions
increased plasma FGF21 concentrations (Laeger et al., 2018). Interest-
ingly, only LP/HF mice showed a significant reduced femur length
compared to CON mice (Fig. 4A). The tibia length was reduced, albeit
insignificantly, in LP/HF mice compared to CON mice (Fig. 4A). In-
terestingly, the femoral cortical thickness was significantly higher in
the LP/HC and lower in the LP/HF mice compared to CON mice
(Fig. 4B). The femoral cortical area ratio was significantly higher in LP/
HC compared to CON and LP/HF mice, whereas the trabecular area
ratio was not different between the 3 groups (Fig. 4C). The analysis of
the BMD showed a significantly lower cortical BMD in the LP/HF vs LP/
HC group, without differences in the cancellous BMD, total BMD, and
plane BMD between all 3 groups (Fig. 4D–E). In respect to the min
moment, both LP/HC and LP/HF was lower, although insignificantly, vs
CON mice (Fig. 4F) and the polar moment was significantly lower in
both LP fed groups compared to CON mice (Fig. 4G). In summary,
Fig. 2. Short-term protein restriction does not induce changes in tibia morphology. At 10 weeks of age, wild-type (WT) and FGF21-deficient (Fgf21 KO) mice were
placed on a control (CON) diet for 5 days, at which point a random subgroup of mice was transferred to the low-protein (LP) diet for 2 weeks. (A) Tibial marrow area.
Tibial cortical (B) thickness, (C) total area, (D) BA/TA, (E) bone porosity, and (F) pMOI. Tibial trabecular (G) total volume, (H) BV/TV, (I) number, (J) thickness, and
(K) connectivity density. Data are presented as means± SEM (n = 10/group). Differences were calculated by using two-way ANOVA. Mean values with different
lowercase letters differ with P ≤ 0.05.
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protein restriction led to negative impacts on the morphology of bones
under high-fat diet conditions.
3.5. Dietary methionine restriction alters bone architecture in New Zealand
Obese mice
To evaluate the effect of dietary methionine restriction on bone
under obese conditions, NZO mice were placed on high-fat diets with a
normal protein content that provided methionine at control (CON) or
low levels (MR) with or without cystine for up to 9 weeks. Only the MR
feeding without cystine (-Cys) increased plasma FGF21 concentrations
(Castaño-Martinez et al., 2019). In general, only the MR (-Cys) mice
showed alterations in bone architecture compared to CON (-Cys) mice
(Fig. 5). All the effects were lost in MR mice fed with cystine, which did
not increase plasma FGF21 levels (Fig. 5). In detail, the femur length
did not differ between the groups, but the tibia length was significantly
shorter in MR vs CON mice without cystine (Fig. 5A–B). The femoral
cortical thickness (Fig. 5C), femoral cortical area ratio (Fig. 5D), and
femoral trabecular area ratio (Fig. 5E) were significantly lower in MR
(-Cys) compared to CON (-Cys) mice. The total BMD and the polar
moment was significantly reduced in MR (-Cys) vs CON (-Cys) mice,
without difference between the groups in the plane BMD (Fig. 5F–H). In
summary, a methionine restriction led to bone loss and a higher fra-
gility under high-fat diet conditions only in the absence of cysteine
when FGF21 was increased in the circulation.
Fig. 3. GCN2 is not required for long-term low-protein-induced changes in femoral morphology. At 14–15 weeks of age, wild-type (WT) and GCN2-deficient (Gcn2
KO) mice were placed on a control (CON) diet for 5 days, at which point a random subgroup of mice was transferred to the low-protein (LP) diet for 27 weeks. (A)
Femur length. Femoral cortical (B) thickness, (C) total area, (D) BA/TA, (E) bone porosity, and (F) pMOI. Femoral trabecular (G) total volume, (H) BV/TV, (I)
number, (J) thickness, and (K) connectivity density. Data are presented as means± SEM (n = 8/group). Differences were calculated by using two-way ANOVA. Mean
values with different lowercase letters differ with P ≤ 0.05.
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4. Discussion
This study presents a systematic evaluation of the impact of dietary
protein restriction on bone morphology in adult, skeletally mature but
not elderly mice, and tests the role of FGF21 and GCN2 as mediators of
this effect. The data indicate that prolonged dietary protein restriction
results in a significantly negative impact on both trabecular and cortical
bone parameters, and these results were consistently reproduced in two
independent animal cohorts. These results also suggest that deletion of
FGF21 not only affects bone morphology as compared to controls, but
also appears to aggravate the effects of protein restriction in trabecular
bone while protecting against diet-induced changes in cortical bone.
GCN2 deletion, in contrast, was largely without effect. This effect can
be explained by the delayed but robustly induced FGF21 increase in
these Gcn2 KO mice (Laeger et al., 2016).
It is well known that deficiency in dietary energy and various nu-
trients (e.g. calcium, phosphorous) negatively impact bone growth and
remodeling in humans and animal models (Talbott et al., 1998; O'uchi
et al., 1999; Riedt et al., 2005; Talbott et al., 2001). Protein has been
demonstrated to be critical for development and bone health in both
humans and animal models. Insufficient dietary protein during devel-
opment has resulted in impaired bone growth and poor bone quality in
adults (Orwoll et al., 1992; Jones et al., 2011; Mardon et al., 2009), and
energy and protein restriction in growing rats impairs peak bone mass
acquisition, resulting in decreased skeletal strength (Mardon et al.,
2009). Moderate dietary protein restriction has also been shown to
reduce bone growth in mice, with the source of protein (casein vs. soy)
differentially impacting the negative changes in bone growth (Rouy
et al., 2014). Our findings in the current study support the previous
data indicating the importance of dietary protein in bone health.
However, the studies presented in the current project were performed
in mice that were nearing skeletal maturity at the onset of protein re-
striction, which indicates an impact of dietary protein restriction on
bone remodeling processes as opposed to bone development. However,
taking into account the effect of protein restriction on cortical thickness
and area, appositional cortical growth may be impaired, and this effect
may be mediated by FGF21. In addition, we were able to obtain these
data using high-resolution μCT, which provides an extensive evaluation
of both cortical and trabecular microarchitecture that can be used to aid
in assessment of overall bone health. We were also able to demonstrate
a negative impact of dietary protein restriction on bone in normal, wild-
type mice, whereas other studies have only found this reduction in bone
remodeling in the presence of comorbidities, such as osteoporosis sec-
ondary to ovariectomy or in aged animals (Bourrin et al., 2000).
Our results demonstrating FGF21 deficiency results in reduced bone
contradict a previous study demonstrating that transgenic mice over-
expressing FGF21 exhibit low bone density and low trabecular bone,
while bone was increased in the same line of FGF21 deficient mice used
in the study by Wei et al (Wei et al., 2012). However, this study pro-
vides no data regarding the age of the mice that were analyzed, and a
more recent follow up study by another group was unable to re-create
the aforementioned decrease in bone density secondary to FGF21
overexpression (Li et al., 2016a). A separate study identified a decrease
in bone density in a setting of high circulating levels of FGF21 sec-
ondary to methionine restriction; however, this study was conducted in
mice that were only 7 weeks of age (Ables et al., 2012), indicating an
effect of protein restriction on bone growth and not only bone re-
modeling as outlined in the present study. Conversely, high protein
Fig. 4. Dietary protein restriction alters bone architecture in New Zealand Obese mice. At 3 weeks of age, NZO mice were placed on a high-fat (CON) diet for 1 week,
at which point two random subgroups of mice were transferred to the LP/HC or LP/HF diet for 8 weeks. (A) Femur and tibia length. (B) Femoral cortical thickness
and (C) cortical and trabecular area ratios. (D) Femoral bone mineral density (BMD), (E) plane BMD, (F) min moment, and (G) polar moment. Data are presented as
mean ± SEM (n = 4/group). Differences between groups were calculated by one-way ANOVA. Mean values with different lowercase letters differ with P≤ 0.05.
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diets have been shown to attenuate bone loss, including in the presence
of energy restriction, and rats fed high protein diets for four weeks
showed an increased bone turnover and volumetric bone mineral
density (Gaffney-Stomberg et al., 2014). Thus, while a large volume of
data support relationships between dietary protein intake on bone
health, contradictory data exist regarding the role of FGF21.
We also tested the impact of methionine restriction on bone mor-
phology in young, skeletally immature mice, and demonstrated a role of
methionine restriction on bone morphology. Skeletally immature mice
were used in this study as the authors wished to prevent type II diabetes
from confounding the experiment; it is difficult to maintain healthy
normoglycemic adult NZO mice because they rapidly develop a hy-
perglycemia as soon as they are placed on a carbohydrate-containing
diet. It is known that vegan and vegetarian diets demonstrate a lower
methionine content, therefore methionine intake is decreased com-
pared to omnivores (McCarty et al., 2009; Schmidt et al., 2016). In-
dividuals adhering to a vegan or vegetarian diet may induce FGF21
levels; indeed, human plasma FGF21 levels have been demonstrated to
be higher in vegetarians and vegans compared to omnivores, and a
short-term change in diet to vegetarianism increased plasma FGF21
levels in omnivores (Castaño-Martinez et al., 2019). As meta-analyses
have suggested that vegetarian diets, and in particular vegan diets (Ho-
Pham et al., 2009), are associated with lower BMD, it can be speculated
that these changes in bone may be associated with higher FGF21 levels.
A strength of this work is that it demonstrates the essential con-
tribution of FGF21 to bone remodeling as a consequence of protein
restriction, effects that we observed in different murine genetic lines.
This impairment was found to be independent of the method by which
protein or methionine restriction was achieved, as long as FGF21 was
ultimately increased. Inclusion of both LP/HC and LP/HF diets in these
studies demonstrates that independent of the substituent for protein
(i.e. FGF21 is increased), the bone architecture is altered, indicating
that FGF21 has profound effects. A limitation of this study, however, is
the absence of direct measurements of bone remodeling parameters
using dynamic histomorphometry. Thus, we are unable to directly link
a diet restricted in protein with a decrease in bone remodeling in mice.
In addition, we were not able to directly evaluate the effect of the
protein-restricted diet on biomechanical strength of the bones, though
the data demonstrate significant effects on pMOI and total cortical area,
which strongly indicate an effect on overall bone strength. Lastly, the
data obtained demonstrating the dietary effects in skeletally mature
mice were derived from two different sites; both long-term studies
utilized femora, whereas the FGF21 short-term data was derived from
tibiae. However, both sites are acceptable for evaluating trabecular and
cortical bone (Bouxsein et al., 2010), and develop using endochondral
ossification at very similar times during embryonic development. In
addition, both bones undergo the same remodeling processes found in
long bones throughout the body. Additionally, as both bones are lo-
cated in the same limb, they experience very similar biomechanical
loads. Taking these limitations into consideration, future work could be
designed with these skeletal endpoints in mind, including consistent
sampling methods, histological preparations for histomorphometry,
and setting aside specific samples for biomechanical testing such as
three-point bending or torsional testing. Histological sections were
evaluated by a boarded veterinary pathologist for any abnormalities in
physes or boney tissue, and while the reduction in trabecular bone
volume in some of the more severely affected treatment groups was
confirmed, no differences in appearance of growth plates were ob-
served. However, it should be noted that all growth plates were inactive
at the timepoints examined. Additional experiments examining growth
Fig. 5. Dietary methionine restriction alters bone architecture in New Zealand Obese mice. At 3 weeks of age, NZO mice were placed on a high-fat diet that provided
methionine at control level (CON) for 1 week, at which point a subgroup of mice was transferred to a methionine-restricted (MR) diet without cystine, MR diet with
cystine, or control diet with cystine for 9 weeks. (A) Femur and (B) tibia length from –Cys group only. (C) Femoral cortical thickness, (D) cortical and (E) trabecular
area ratios. (F) Femoral bone mineral density (BMD), (G) plane BMD, and (H) polar moment. Data are presented as mean ± SEM (n = 5–6/group). Differences
between groups were calculated by two-tailed t-test. *p ≤ 0.05; **p ≤ 0.01.
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plates of younger WT mice with active growth plates may allow for
evaluation for alterations in bone growth. We also did not evaluate the
mechanical properties of bone, which will ultimately provide the like-
lihood of fracture that is an important factor in overall bone health in
humans.
The mechanisms for the decrease in bone identified in the present
study are currently unknown. Further, the mechanism by which sys-
temically elevated FGF21 is protecting against long-term diet-induced
changes in cortical bone is unclear. It has been shown that circulating
IGF-1 levels were reduced in mice fed a low protein diet (Brennan-
Speranza et al., 2011). GH is a well-known stimulator of IGF-1, and
both GH and IGF-1 have significant roles in regulating bone growth
(Olney, 2003). GH directly, as well as through IGF-1, stimulate osteo-
blast proliferation and activity, promoting bone formation. Indeed,
both have been implicated as successful in therapies for osteoporosis
and factures (Locatelli and Bianchi, 2014). In turn, FGF21 has been
shown to inhibit growth hormone (GH) signaling (Inagaki et al., 2008),
as has protein undernutrition (Ammann et al., 2000). Therefore, there is
a potential pathway that FGF21, by negatively impacting GH/IGF-1
signaling, would have a negative impact on bone remodeling in adult
mice. Particularly, overexpression of IGF-1 in mouse osteoblasts was
able to negate the effects of protein restriction for eight weeks in elderly
mice (Brennan-Speranza et al., 2011). Future studies would involve
evaluating whether the GH/IGF-1 pathway is directly involved in
FGF21-mediated bone remodeling. Another potential mechanism is
through osteoblastic differentiation. In vascular smooth muscle cells it
has been shown that FGF21 is suppressing bone morphogenic protein-2
(BMP-2) mRNA expression (Cao et al., 2017a; Cao et al., 2017b), which
is a potent osteogenic protein required for osteoblast differentiation and
bone formation (Cai et al., 2012). FGF21 inhibits osteoblast differ-
entiation and vascular calcification in vitro by the BMP-2/Smad sig-
naling pathway (Liu et al., 2018), and could inhibit the osteogenic
differentiation in human bone mesenchymal stem cells (hBMSCs) under
hyperglycemic conditions (Li et al., 2016b). Future work could include
in vitro studies to further clarify the mechanisms responsible for the
effect on bone outlined herein.
5. Conclusion
Overall, this study demonstrates a negative impact of dietary pro-
tein restriction on bone mass and architecture in adult mice in the
absence of comorbidities, as well as in the NZO mouse model that is
affected by hyperglycemia and insulin resistance. We also identified
that short-term interventions of dietary restriction do not appear to
impair the bone architecture, and that reduced bone strength identified
in humans engaging in vegetarian or vegan diets may be the con-
sequence of increased FGF21 levels. Therefore, we conclude that FGF21
is implicated in the protein-restriction-mediated modulation of bone
remodeling.
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